Phenomex Inc's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Phenomex Inc (CELL) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Phenomex Inc vs Its Competitors
- TTM: Trailing 12-month revenue of 72M vs 17,420M combined for its competitors (0.4% combined share).
- Trending: Latest-quarter revenue run-rate is decelerating (-21.8% annualized vs trailing 12 months), vs decelerating (-22.8%) for its tracked peer group.
- Growth: Phenomex Inc generated -26.7% revenue growth year over year in Q2 2023, vs 10.1% for its competitors combined.
- Profitability: Its -357.8% net margin compares with 10.8% for the peer group.
- Peer revenue share: Phenomex Inc accounted for 0.4% of combined revenue among its tracked peer group, down from 0.6% a year earlier.
- Peer differentiation: Revenue per employee of $0.63M compares with $0.99M for the peer group (0.6x).
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
CELL Sales vs. its Competitors, Q2 2023
Phenomex Inc reported revenue contraction of 26.67 % year on year in Q2 2023, below its competitors' combined revenue growth of 10.11 %.
With a net margin of -357.79 %, Phenomex Inc reported lower profitability than its competitors (10.83 %).
Phenomex Inc generated 0.42 % of the combined sales of its peer group, down from 0.62 % a year earlier.
API endpoints for this dataset
Phenomex Inc vs. its Competitors, Q2 2023
Revenue growth, year on year
Net margin
Revenue run-rate vs trailing 12 months
TTM net margin
TTM = trailing twelve months. Run-rate annualizes the latest quarter (×4) and compares it to TTM. In millions of $. High-Confidence Competitors are named as a competitor directly in Phenomex Inc reports; Similar-Size Competitors are the closest peers by market-cap rank within the same industry; Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC, all independent of the competitor list.
TTM revenue, latest-quarter run-rate and net income/margin benchmarked across Phenomex Inc and its 4 competitor groupings. Available under Commercial License.
| Entity | TTM Revenue | Rev Run-rate vs TTM |
|---|---|---|
| Phenomex Inc | $12,345M | +12.3% · Accelerating |
| Competitors combined | $12,345M | +12.3% · Accelerating |
| High-Confidence Competitors (9) | $12,345M | +12.3% · Accelerating |
TTM revenue, run-rate and net margin benchmarking across Phenomex Inc's competitor groups requires a Commercial License.
For context: the Laboratory Analytical Instruments industry grew revenue 13.0% year over year, combined, vs -26.7% for Phenomex Inc. Phenomex Inc's share of combined industry revenue moved from 0.20% to 0.13%, a loss of 0.07 percentage points.
Phenomex Inc's Competitor Quality Breadth
Group definitions: see Methodology: Performance Group Definitions.
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Phenomex Inc | - | No | No | Yes |
| Competitors combined (9) | ||||
| High-Confidence Competitors (9) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
CELL Stock Performance relative to its Competitors
CELL Stock Performance relative to High-Confidence Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Zymeworks Inc | 282.9% | Outperformed |
| 2 | Regeneron Pharmaceuticals Inc | 282.9% | Outperformed |
| 3 | Beam Therapeutics Inc | 282.9% | Outperformed |
| 4 | Ginkgo Bioworks Holdings Inc | 282.9% | Outperformed |
| 5 | Editas Medicine Inc | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Phenomex Inc's best-performing competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Publicly Traded Peers of Phenomex Inc
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
 Phenomex Inc |
98.71 | 71.80 |
 Regeneron Pharmaceuticals Inc |
95,438.47 | 16,896.20 |
 Crispr Therapeutics Ag |
4,840.92 | 25.17 |
 Beam Therapeutics Inc |
2,828.95 | 146.64 |
 Zymeworks Inc |
2,183.96 | 37.13 |
 Intellia Therapeutics Inc |
1,697.65 | 52.89 |
| SUBTOTAL | 108,305.30 | 17,491.82 |
Sign in to see all competitors of Phenomex Inc .
Sources: see Methodology: Peer & Competitor Identification, Sourcing.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Phenomex Inc versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Phenomex Inc's Competitors Named by the Company
Competitive relationships identified from Phenomex Inc reports and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| Omniab Inc | Company report | 85% |
| Abcellera Biologics Inc | Company report | 85% |
| Agilent Technologies inc | Company report | 85% |
| 908 Devices inc | Company report | 85% |
| Nautilus Biotechnology Inc | Company report | 85% |
| Akoya Biosciences Inc | Company report | 85% |
| T2 Biosystems Inc | Company report | 85% |
| Absci Corp | Company report | 85% |
| Presurance Holdings Inc | Company report | 85% |
| CNFR | Company report | 85% |
| Avantor Inc | Company report | 85% |
| Bio rad Laboratories Inc | Company report | 85% |
| Mettler toledo International Inc | Company report | 85% |
| Cytek Biosciences Inc | Company report | 85% |
| Revvity Inc | Company report | 85% |
| Astrotech Corp | Company report | 85% |
| Danaher Corporation | Company report | 85% |
| 10x Genomics Inc | Company report | 85% |
| Harvard Bioscience Inc | Company report | 85% |
| Thermo Fisher Scientific Inc | Company report | 85% |
| Olink Holding Ab publ | Company report | 85% |
| Standard Biotools Inc | Company report | 85% |
| Telesis Bio Inc | Company report | 85% |
| Illumina Inc | Company report | 85% |
| Singular Genomics Systems Inc | Company report | 85% |
Company report basis, confidence, active dates and source counts for Phenomex Inc's named competitors require a Commercial License.
Methodology: see Methodology: Peer & Competitor Identification, Sourcing.
Phenomex Inc's Business Segment Mix vs Peers
Revenue by operating segment or division, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).| Company | Largest Segment |
|---|---|
| Intellia Therapeutics Inc | Development of Gene Editing Based Therapies 100.00 % |
| Ginkgo Bioworks Holdings Inc | Reportable 100.00 % |
| Editas Medicine Inc | Reportable 100.00 % |
| Bionano Genomics Inc | Reportable Segment 100.00 % |
Source: operating segment revenue as reported in each company's reports (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).
Phenomex Inc's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Phenomex Inc | 99 | 629,807 | -1,092,377 |
| Regeneron Pharmaceuticals Inc | 95,438 | 1,096,444 | 312,615 |
| Crispr Therapeutics Ag | 4,841 | 125,234 | -2,269,328 |
| Beam Therapeutics Inc | 2,829 | 286,975 | -209,597 |
| Zymeworks Inc | 2,184 | 140,633 | -568,152 |
| Intellia Therapeutics Inc | 1,698 | 140,284 | -1,130,334 |
| PEERS TOTAL | 108,207 | 986,355 | 181,956 |
Phenomex Inc's Geographic Revenue Exposure vs Peers
Revenue by country/region as reported in each company's most recent report. Disclosure granularity varies by filer (some report by country, others by broad region) and is shown as disclosed.| Company | Largest Market |
|---|---|
| Bionano Genomics Inc | EMEA 59.25 % |
Source: revenue geography as reported in each company's reports (10-K/10-Q), via the CSIMarket API. Percentages are of that company's own total consolidated revenue for its most recent reported period.
Phenomex Inc's Profitability & Cost Structure
Trailing 12-month margins from SEC-filed financials. Operating margin is compared to the Laboratory Analytical Instruments industry median; gross margin, EBITDA margin and capital intensity are compared to the live industry average (49 companies). See the full Laboratory Analytical Instruments industry profitability benchmarks.| Metric | Company | Industry | Difference |
|---|---|---|---|
| Gross Margin | 64.76 % | 34.50 % (avg) | +30.3 pp |
| Operating Margin | - | industry median | - |
| EBITDA Margin | - | -12.73 % (avg) | - |
| Capital Intensity (Capex / Revenue) | 2.47 % | 3.87 % (avg) | -1.4 pp |
Source: CSIMarket API, trailing 12 months. SG&A and R&D as a share of revenue have limited coverage as this data is backfilled and appear only where reported. Higher capital intensity is not inherently negative; it reflects the industry's asset requirements.
Phenomex Inc's Valuation vs Competitive Position
Valuation multiples vs the Laboratory Analytical Instruments industry average (49 companies, excluding loss-making/negative-equity outliers), alongside returns on capital for context on whether a premium or discount lines up with measurably stronger or weaker returns. See the full Laboratory Analytical Instruments industry valuation benchmarks.| Metric | Company | Industry Average | Difference |
|---|---|---|---|
| P/E | - | 33.2x | - |
| EV / EBITDA | - | 20.6x | - |
| P/B | 0.4x | 2.9x | -2.5x |
| Return on Equity | -87.50 % | industry aggregate | -79.53 % |
| Return on Invested Capital | -36.21 % | -10.58 % (avg) | -25.63 % |
Source: CSIMarket API, trailing 12 months. A valuation premium or discount is not, by itself, a judgment of over- or under-valuation. Compare it against the return and growth context shown elsewhere on this page.
Phenomex Inc's Multi-Year Financial Trajectory
Fiscal-year revenue growth, operating margin, return on invested capital and P/E, as reported in company reports.| Metric | 2020 | 2021 | 2022 |
|---|---|---|---|
| Revenue Growth | 13.42 % | 32.79 % | -7.96 % |
| Operating Margin | -12.80 % | -82.90 % | - |
| Return on Invested Capital | -2.36 % | -14.48 % | -26.03 % |
| P/E | - | - | - |
Source: CSIMarket API, fiscal-year figures. P/E is this company's own historical ratio at each fiscal year end and can swing sharply around an earnings trough: that is real, not a data error.
Phenomex Inc's Competitive Forces (Porter's Five Forces)
Only the forces this data can support honestly are shown; the other three are marked as such rather than guessed.| Force | Assessment | Basis |
|---|---|---|
| Barriers to Entry | Lower than typical for the industry | Capital intensity (capex / revenue) of 2.47 % vs industry average 3.87 % (see Profitability & Cost Structure above) |
Note: see Methodology: Porter's Five Forces. Supplier power and buyer power are covered on Phenomex Inc's dedicated Suppliers and Customers pages, not here.
Phenomex Inc's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
No rule matched.
Weaknesses
- Return on equity 79.5 points below the industry aggregate.
- Latest-quarter revenue run-rate is decelerating (-21.8% annualized vs trailing 12 months).
- Piotroski F-Score of 2 or below, the standard financial-distress signal.
Opportunities
- A meaningful share of competitors (44.40 %) show financial-distress signals, a possible opening to gain share.
Threats
- Tracked peer group's revenue run-rate is broadly decelerating (-22.8% annualized).
Methodology: see Methodology: SWOT Analysis.
Phenomex Inc's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Phenomex Inc | 1.71 | 3.45 | 0.19 |
| Regeneron Pharmaceuticals Inc | 0.58 | 3.56 | 0.06 |
| Crispr Therapeutics Ag | 2.24 | 16.26 | 0.25 |
| Beam Therapeutics Inc | 5.97 | 14.30 | 0.07 |
| Zymeworks Inc | 3.17 | 7.32 | - |
| Intellia Therapeutics Inc | 1.62 | 5.97 | 0.03 |
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Phenomex Inc's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Phenomex Inc | Q2 2023 | -26.7 % | - |
| Regeneron Pharmaceuticals Inc | Q3 2026 | +36.3 % | +33.5 % |
| Crispr Therapeutics Ag | Q3 2026 | +1,325.1 % | - |
| Beam Therapeutics Inc | Q3 2026 | -96.8 % | - |
| Zymeworks Inc | Q2 2026 | -90.6 % | - |
| Intellia Therapeutics Inc | Q3 2026 | -48.0 % | - |
| PEERS TOTAL | +33.4 % | +39.8 % |
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Phenomex Inc's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Phenomex Inc | Q2 2023 | +28.5 % | -98.2 % |
| Regeneron Pharmaceuticals Inc | Q3 2026 | +104.1 % | +49.1 % |
| Crispr Therapeutics Ag | Q3 2026 | - | +459.5 % |
| Beam Therapeutics Inc | Q3 2026 | - | -75.8 % |
| Zymeworks Inc | Q2 2026 | - | - |
| Intellia Therapeutics Inc | Q3 2026 | - | +2,962.1 % |
Phenomex Inc's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Phenomex Inc | - | - | - |
| Regeneron Pharmaceuticals Inc | 11.50% | 13.00% | 15.07% |
| Crispr Therapeutics Ag | - | - | - |
| Beam Therapeutics Inc | - | - | - |
| Zymeworks Inc | - | - | - |
| Intellia Therapeutics Inc | - | - | - |
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Phenomex Inc's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Phenomex Inc | - | 1.37 |
| Regeneron Pharmaceuticals Inc | 19.99 | 5.65 |
| Crispr Therapeutics Ag | - | 192.31 |
| Beam Therapeutics Inc | - | 19.29 |
| Zymeworks Inc | - | 58.82 |
| Intellia Therapeutics Inc | - | 32.10 |
| PEERS AVERAGE | 35.06 | 6.19 |
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.